Efficacy and Safety Phase III Clinical Study of VC005 Tablets in Subjects With Active Ankylosing Spondylitis.
Trial Parameters
Brief Summary
This clinical trial is a multicenter, randomized, double-blind, controlled phase III clinical study.
Eligibility Criteria
Inclusion Criteria: * The subject understands and voluntarily signs the informed consent form (ICF) and is willing and able to comply with the study protocol; * The subject is between 18 and 70 years of age (including borderline values) at the time of signing the ICF, regardless of gender; * The subject has been diagnosed with AS according to the 1984 New York Revised Criteria for Ankylosing Spondylitis Exclusion Criteria: * Those who may be allergic to VC005, similar drugs or their excipients. * Individuals who have undergone organ transplantation in the past and require continuous use of immunosuppressants. * Those who, for any reason, are considered by the investigator to be unsuitable for participation in this study.